Horizon Discovery Strengthens Board with Appointment of Dr Ian Gilham

Horizon Discovery (Horizon), a leading provider of research tools to support the development of personalised medicines, has announced the appointment of Dr Ian Gilham as a non-executive director.

Ian is currently non-executive chairman of Multiplicom NV, focused on the development and commercialization of DNA sequencing products; and Biosurfit SA, focused on development and commercialisation of point-of-care diagnostic products. He is also director of Stowheath Ltd., which offers advisory services to private equity companies and corporate finance organizations investing in clinical diagnostics and medical device companies. Ian has previously been CEO of Axis-Shield plc and Vice President, Pharmacogenetics and Diagnostics at GSK, as well as holding various positions within Abbott Laboratories.

Commenting on the announcement, Dr Darrin M Disley, CEO of Horizon said: “I would like to welcome Ian to Horizon’s board of directors. His commercial and investor relations experience will be highly valuable to the company as we continue to develop as a world-leading translational genomics organisation.”

Dr Gilham noted: “Horizon is one of the UK’s most promising life science companies. I’m delighted to join the board at this stage of the organisation’s development.”

Horizon’s mission is to provide its customers with cutting-edge biological tools and services that will accelerate the pace of development of ‘personalized’ medicines.